Resistance To Immunotoxins In Cancer Therapy Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Resistance To Immunotoxins In Cancer Therapy book. This book definitely worth reading, it is an incredibly well-written.
Resistance to Immunotoxins in Cancer Therapy by Rama Shanker Verma,Benjamin Bonavida Pdf
This volume is a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.
Cytotoxins and Immunotoxins for Cancer Therapy by Koji Kawakami,Bharat B. Aggarwal,Raj K. Puri Pdf
Recent advances in cytotoxins and immunotoxins are accelerating our understanding of cancer and leading to more effective therapeutic treatments. Although a large number of articles have been published on these cytotoxins and immunotoxins, this important information has yet to be compiled into one comprehensive resource. For the first time,
Resistance to Immunotoxins in Cancer Therapy by Rama Shanker Verma,Benjamin Bonavida Pdf
This book will be a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.
Chimeric Toxins by Haya Lorberboum-Galski,Philip Lazarovici Pdf
Bacteria and plants produce powerful toxins that can cause a variety of diseases, some of which are lethal for many animal species. The mechanisms of action are common to many of these toxins and represent general pathways for the interaction of a number of biomolecules with target cells, such as binding to specific surface receptors, internalizati
Cancer has been a patient-specific and difficult-to-treat disease for decades, resulting in more deaths since 1900 than all other diseases except cardiovascular diseases. As societies around the world continue to shift towards an aging population, the social and economic burden created by cancer will only rise in the coming decades, necessitating continued improvement in our cancer therapies. Remarkably, in the late 1800s, bone surgeon William Coley serendipitously discovered that bacteria could be administered to patients as an effective (and sometimes toxic) form of cancer therapy known as "Coley's Toxins". His discoveries unknowingly led to two fields of cancer therapy that have been in development for decades and are now leading to significant improvements in therapy for cancer patients: immune-based and toxin-based therapies for cancer. Articles included here discuss the discoveries that emerged from Coley's Toxins that enable us to harness the immune system and microbial toxins to combat cancers, as oncology shifts from a field dominated by chemotherapy for most of the 20th century to biologic therapies that will dominate the 21st century.
Monoclonal Antibodies in Cancer by Stewart Sell,Ralph Reisfeld Pdf
This represents the third volume in a series on cancer markers pub lished by the Humana Press. The first volume, published in 1980, stressed the relationship of development and cancer as reflected in the production of markers by cancer that are also produced by normal cells during fetal development. The concept that cancer represents a problem of differentiation was introduced by Barry Pierce in describing differenti ation of teratocarcinomas. Highlighted were lymphocyte markers, alphafetoprotein, carcinoembryonic antigen, ectopic hormones, enzymes and isozymes, pregnancy proteins, and fibronectin. The second volume, published in 1982 and coedited with Britta Wahren, focused on the diagnostic use of oncological markers in human cancers, which were systematically treated on an organ by organ basis. At that time, the application of monoclonal antibodies to the identification of cancer markers was still in a very preliminary stage. A general introduc tion to monoclonal antibodies to human tumor antigens was given there by William Raschke, and other authors included coverage of those mark ers then detectable by monoclonal antibodies in their chapters.
Toxin and Immunotoxin Based Therapeutic Approaches by Massimo Bortolotti,Letizia Polito,Andrea Bolognesi Pdf
In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich's insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied antibody-based targeting strategies is the carrying of powerful toxins. The generated molecules are immunotoxins, i.e., chimeric proteins obtained by coupling bacterial or plant toxins and antibodies through chemical linking or genetic engineering. Immunotoxins are functionally designed to eliminate the cells responsible for pathological conditions, and they find applications in several fields, ranging from cancer to immunological diseases or pain control. Despite the lack of specificity, even native toxins find clinical application, but the use of unconjugated toxins is limited to loco-regional treatments. A fundamental requirement for the medical application of toxins and their immunoconjugates is in-depth knowledge of their interaction with target cells in terms of binding, uptake, intracellular routing, and substrate specificity. This Special Issue focuses on toxins and immunotoxins that have clinical potential. We hope to give the reader a comprehensive overview of new toxin delivery strategies and toxin-based experimental disease models, both in vitro and in vivo.
Topics in Anti-Cancer Research: Volume 8 by Atta-ur-Rahman,Khurshid Zaman Pdf
Topics in Anti-Cancer Research covers new developments in the field of cancer. Novel drugs as anticancer agents include natural and synthetic phenazines and other anti-cancer compounds. It also encompasses the role of estrogen as endocrine disruptors and strategies targeting cancer stem cells for the treatment of different types of cancers, including myeloma and renal cell cancer. The diversity of researches and topics published in this eBook Series will be valuable to cancer researchers, clinicians, and cancer professionals aiming to develop novel anti-cancer targets for the treatment of various cancers. The topics covered in the eighth volume of this series are as follows: -Novel Drugs for Multiple Myeloma -Synthetic Estrogens are Endocrine Disruptors via Inhibition of AF1 Domain of ERs -Recent Progress of Phenazines as Anticancer Agents -Cancer Stem Cell Targeting for Anticancer Therapy: Strategies and Challenges
Author : Walter A. Hall Publisher : Springer Science & Business Media Page : 305 pages File Size : 40,5 Mb Release : 2008-02-02 Category : Medical ISBN : 9781592591145
Immunotoxin Methods and Protocols by Walter A. Hall Pdf
Immunotoxins represent a new class of human therapeutics that have widespread applications and a potential that has not yet been fully recognized since they were first conceived of by Paul Ehrlich in 1906. The majority of advances in the development and implementation of immunotoxins has occurred over the last 20 years. The reasons for this use of immunotoxins in basic science and clinical research are the powerful concurrent advances in genetic engineering and receptor physiology. Recombinant technology has allowed investigators to produce sufficient quantities of a homogeneous c- pound that allows clinical trials to be performed. The identification of specific receptors on malignant cell types has enabled scientists to generate immunotoxins that have had positive results in clinical trials. As more cellular targets are identified in coming years, additional trials will be conducted in different disease states affecting still larger patient populations. Modulation of the immune system to decrease the humoral response to immunotoxins may improve their overall efficacy. As increasingly more effective compounds are generated, it will be necessary to decrease the local and systemic toxicity - sociated with these agents, and methods for doing so are presently being - veloped. The work presented in Immunotoxin Methods and Protocols focuses on three specific areas of immunotoxin investigation that are being conducted by experts throughout the world. The first section describes the construction and development of a variety of immunotoxins.
Author : David E Thurston,Paul J M Jackson Publisher : Royal Society of Chemistry Page : 502 pages File Size : 47,9 Mb Release : 2019-07-11 Category : Medical ISBN : 9781788018456
Cytotoxic Payloads for AntibodyDrug Conjugates by David E Thurston,Paul J M Jackson Pdf
Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (KadcylaTM), brentuximab vedotin (AdcetrisTM), inotuzumab ozogamicin (BesponsaTM), gemtuzumab ozogamicin (MylotargTM) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many. The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity. Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future.
Author : Stefan R. Schmidt Publisher : John Wiley & Sons Page : 995 pages File Size : 42,8 Mb Release : 2013-01-28 Category : Medical ISBN : 9781118354582
Fusion Protein Technologies for Biopharmaceuticals by Stefan R. Schmidt Pdf
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs—with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched. Fusion Protein Technologies for Biopharmaceuticals examines the state of the art in developing fusion proteins for biopharmaceuticals, shedding light on the immense potential inherent in fusion protein design and functionality. A wide pantheon of international scientists and researchers deliver a comprehensive and complete overview of therapeutic fusion proteins, combining the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs designed for as yet unmet medical needs. The book covers the major types of fusion proteins—receptor-traps, immunotoxins, Fc-fusions and peptibodies—while also detailing the approaches for developing, delivering, and improving the stability of fusion proteins. The main body of the book contains three large sections that address issues key to this specialty: strategies for extending the plasma half life, the design of toxic proteins, and utilizing fusion proteins for ultra specific targeting. The book concludes with novel concepts in this field, including examples of highly relevant multifunctional antibodies. Detailing the innovative science, commercial realities, and brilliant potential of fusion protein therapeutics, Fusion Protein Technologies for Biopharmaceuticals is a must for pharmaceutical scientists, biochemists, medicinal chemists, molecular biologists, pharmacologists, and genetic engineers interested in determining the shape of innovation in the world of biopharmaceuticals.
This comprehensive encyclopedic reference provides rapid access to focused information on topics of cancer research for clinicians, research scientists and advanced students. Given the overwhelming success of the first edition, which appeared in 2001, and fast development in the different fields of cancer research, it has been decided to publish a second fully revised and expanded edition. With an A-Z format of over 7,000 entries, more than 1,000 contributing authors provide a complete reference to cancer. The merging of different basic and clinical scientific disciplines towards the common goal of fighting cancer makes such a comprehensive reference source all the more timely.
John Mendelsohn,Peter M. Howley,Mark A. Israel,Joe W. Gray,Craig B. Thompson
Author : John Mendelsohn,Peter M. Howley,Mark A. Israel,Joe W. Gray,Craig B. Thompson Publisher : Elsevier Health Sciences Page : 1948 pages File Size : 46,8 Mb Release : 2008-04-01 Category : Medical ISBN : 9781437710991
The Molecular Basis of Cancer by John Mendelsohn,Peter M. Howley,Mark A. Israel,Joe W. Gray,Craig B. Thompson Pdf
Successfully fighting cancer starts with understanding how it begins. This thoroughly revised 3rd Edition explores the scientific basis for our current understanding of malignant transformation and the pathogenesis and treatment of cancer. A team of leading experts thoroughly explain the molecular biologic principles that underlie the diagnostic tests and therapeutic interventions now being used in clinical trials and practice. Incorporating cutting-edge advances and the newest research, the book provides thorough descriptions of everything from molecular abnormalities in common cancers to new approaches for cancer therapy. Features sweeping updates throughout, including molecular targets for the development of anti-cancer drugs, gene therapy, and vaccines...keeping you on the cutting edge of your specialty. Offers a new, more user-friendly full-color format so the information that you need is easier to find. Presents abundant figures-all redrawn in full color-illustrating major concepts for easier comprehension. Features numerous descriptions of the latest clinical strategies-helping you to understand and take advantage of today’s state-of-the-art biotechnology advances.
Immunopharmacology in Autoimmune Diseases and Transplantation by L. Endresen,Ø. Førre,H.E. Rugstad Pdf
This book incorporates the latest advances in immunopharmacological treatment. One objective has been to provide appropriate bridges between the basic sciences of immunology and pharmacology on the one hand and clinical medicine on the other. A further intention has been to emphasize those advances in immunology and pharmacology that are of clinical importance while retaining those facts that, while not new, remain clinically useful. The immunology section provides the necessary background for immunopharmacologi cal treatment. The chapters on individual cell types include normal surface markers, mode of activation, and activation markers and functions in health and disease. The chapters on pharmacology give comprehensive information on immunosuppressive drugs in regular use today, their biochemical and cellular mechanisms of action, pharmaco kinetics, dosage regimens, therapeutic responses, adverse reactions, and drug interactions and tolerance. In addition, certain therapeutic principles that are still in an experimental phase are described, for example, immunotoxins, thymic hormones, and interleukins. The book presents comprehensive information on various autoimmune diseases, the etiopathogenetic immune mechanisms where these are known, and the current possibilities for immunopharmacological intervention. The specific disease section also covers rare situations, fluctuations in disease patterns, and subgroups of patients and immunophar macological treatment in these situations. Altogether, the book represents a practical textbook for clinicians and advanced students who want to be updated on therapeutic principles with regard to autoimmune diseases and transplantation.
The exquisite binding specificity of antibodies has made them valuable tools from the laboratory to the clinic. Since the description of the murine hybridoma technology by Köhler and Milstein in 1975, a phenomenal number of mo- clonal antibodies have been generated against a diverse array of targets. Some of these have become indispensable reagents in biomedical research, while others were developed for novel therapeutic applications. The attractiveness of an- bodies in this regard is obvious—high target specificity, adaptability to a wide range of disease states, and the potential ability to direct the host’s immune s- tem for a therapeutic response. The initial excitement in finding Paul Ehrlich’s “magic bullet,” however, was met with widespread disappointment when it was demonstrated that murine antibodies frequently elicit the human anti-murine an- body (HAMA) response, thus rendering them ineffective and potentially unsafe in humans. Despite this setback, advances in recombinant DNA techniques over the last 15–20 years have empowered the engineering of recombinant antibodies with desired characteristics, including properties to avoid HAMA. The ability to p- duce bulk quantities of recombinant proteins from bacterial fermentation also fueled the design of numerous creative antibody constructs. To date, the United States Food and Drug Administration has approved more than 10 recombinant antibodies for human use, and hundreds more are in the development pipeline. The recent explosion in genomic and proteomic information appears ready to deliver many more disease targets amenable to antibody-based therapy.